|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
1,430,000,000 |
Market
Cap: |
97.41(B) |
Last
Volume: |
6,619,168 |
Avg
Vol: |
8,474,413 |
52
Week Range: |
$48.64 - $68.84 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 297 |
Guru Rank Value : 4.1 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Boston Scientific develops, manufactures and markets medical devices. Co.'s Medical Surgical segment consist of: Endoscopy, which develops and manufactures devices to diagnose and treat a range of gastrointestinal and pulmonary conditions; and Urology and Pelvic Health, which develops and manufactures devices to treat various urological and pelvic conditions. Co.'s Rhythm and Neuro segment includes: Cardiac Rhythm Management, which develops and manufactures implantable devices to treat cardiac abnormalities; and Electrophysiology, which develops and manufactures medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
86,763 |
367,796 |
891,893 |
1,873,129 |
Total Sell Value |
$5,815,387 |
$21,391,604 |
$49,075,093 |
$91,423,659 |
Total People Sold |
6 |
8 |
11 |
13 |
Total Sell Transactions |
9 |
19 |
36 |
71 |
End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Ballinger Kevin J. |
SVP & Pres, Interven Cardio |
|
2013-10-28 |
4 |
D |
$11.58 |
$10,098 |
D/D |
(872) |
78,481 |
|
- |
|
Ballinger Kevin J. |
SVP & Pres, Interven Cardio |
|
2013-10-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,594 |
79,353 |
|
- |
|
Capello Jeffrey D |
EVP & Chief Financial Officer |
|
2013-08-29 |
4 |
S |
$10.67 |
$5,607,309 |
D/D |
(525,000) |
147,447 |
|
- |
|
Capello Jeffrey D |
EVP & Chief Financial Officer |
|
2013-08-29 |
4 |
OE |
$7.41 |
$3,519,750 |
D/D |
475,000 |
535,909 |
|
- |
|
Fitzgerald Joseph Michael |
SVP & President, CRM |
|
2013-08-16 |
4 |
S |
$11.02 |
$101,420 |
D/D |
(9,202) |
93,191 |
|
- |
|
Ballinger Kevin J. |
SVP & Pres, Interven Cardio |
|
2013-08-14 |
4 |
S |
$11.28 |
$430,630 |
D/D |
(38,171) |
73,519 |
|
- |
|
Fitzgerald Joseph Michael |
SVP & President, CRM |
|
2013-07-29 |
4 |
D |
$10.97 |
$24,573 |
D/D |
(2,240) |
98,149 |
|
- |
|
Fitzgerald Joseph Michael |
SVP & President, CRM |
|
2013-07-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,665 |
100,389 |
|
- |
|
Onuscheck John Michael |
SVP & President, EMEA |
|
2013-07-29 |
4 |
D |
$10.97 |
$24,156 |
D/D |
(2,202) |
73,793 |
|
- |
|
Onuscheck John Michael |
SVP & President, EMEA |
|
2013-07-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,165 |
75,995 |
|
- |
|
Mirviss Jeffrey B. |
SVP&Pres, Periph Intervent |
|
2013-07-28 |
4 |
D |
$10.96 |
$12,396 |
D/D |
(1,131) |
65,190 |
|
- |
|
Mirviss Jeffrey B. |
SVP&Pres, Periph Intervent |
|
2013-07-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,364 |
66,321 |
|
- |
|
Pierce David A |
SVP and President, Endoscopy |
|
2013-07-28 |
4 |
D |
$10.96 |
$844 |
D/D |
(77) |
25,600 |
|
- |
|
Pierce David A |
SVP and President, Endoscopy |
|
2013-07-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
234 |
25,677 |
|
- |
|
Prange Karen |
SVP&Pres, Uro & Womens Health |
|
2013-07-02 |
4 |
D |
$9.17 |
$77,321 |
D/D |
(8,432) |
17,430 |
|
- |
|
Prange Karen |
SVP&Pres, Uro & Womens Health |
|
2013-07-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,862 |
25,862 |
|
- |
|
Capello Jeffrey D |
EVP & Chief Financial Officer |
|
2013-06-16 |
4 |
D |
$9.51 |
$59,980 |
D/D |
(6,307) |
197,447 |
|
- |
|
Capello Jeffrey D |
EVP & Chief Financial Officer |
|
2013-06-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,665 |
203,754 |
|
- |
|
Mirviss Jeffrey B. |
SVP&Pres, Periph Intervent |
|
2013-05-31 |
4 |
S |
$9.36 |
$102,467 |
D/D |
(10,941) |
62,957 |
|
- |
|
Carruthers Wendy |
SVP, Human Resources |
|
2013-05-30 |
4 |
S |
$9.14 |
$228,939 |
D/D |
(25,001) |
19,158 |
|
- |
|
Connors Nelda J |
Director |
|
2013-05-29 |
4 |
S |
$9.17 |
$221,144 |
D/D |
(24,116) |
0 |
|
- |
|
Capello Jeffrey D |
EVP & Chief Financial Officer |
|
2013-05-12 |
4 |
D |
$8.45 |
$19,934 |
D/D |
(2,359) |
189,089 |
|
- |
|
Capello Jeffrey D |
EVP & Chief Financial Officer |
|
2013-05-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,235 |
191,448 |
|
- |
|
Byrnes Bruce L |
Director |
|
2013-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
22,756 |
98,920 |
|
- |
|
Reinhardt Uwe E |
Director |
|
2013-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
22,756 |
146,202 |
|
- |
|
1824 Records found
|
|
Page 9 of 73 |
|
|